Venclexta Success In Second VIALE Study Sets Up Potential Full Approval In AML

 
• By Joseph Haas

Weeks after their first combo study with Venclexta in first-line AML failed, AbbVie and Genentech reported top-line data showing that the BCL-2 inhibitor plus azacitidine improved survival and remission rates.

Leukemia
New data may position Venclexta for full approval in acute myeloid leukemia

More from Clinical Trials

More from R&D